Gaskin Darrell J, Weinfurt Kevin P, Castel Liana D, DePuy Venita, Li Yun, Balshem Andrew, Benson Al, Burnett Caroline B, Corbett Sandra, Marshall John, Slater Elyse, Sulmasy Daniel P, Van Echo David, Meropol Neal J, Schulman Kevin A
Department of Health Policy and Management, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Med Decis Making. 2004 Nov-Dec;24(6):614-24. doi: 10.1177/0272989X04271041.
The authors sought to empirically test whether relative health stock, a measure of patients' sense of loss in their health due to illness, influences the treatment decisions of patients facing life-threatening conditions. Specifically, they estimated the effect of relative health stock on advanced cancer patients' decisions to participate in phase I clinical trials.
A multicenter study was conducted to survey 328 advanced cancer patients who were offered the opportunity to participate in phase I trials. The authors asked patients to estimate the probabilities of therapeutic benefits and toxicity, their relative health stock, risk preference, and the importance of quality of life.
Controlling for health-related quality of life, an increase in relative health stock by 10 percentage points reduced the odds of choosing to participate in a phase I trial by 16% (odds ratio = 0.84, 95% confidence interval = 0.72, 0.97).
Relative health stock affects advanced cancer patients' treatment decisions.
作者试图通过实证检验相对健康存量（一种衡量患者因疾病而产生的健康损失感的指标）是否会影响面临危及生命状况的患者的治疗决策。具体而言，他们估计了相对健康存量对晚期癌症患者参与I期临床试验决策的影响。
开展了一项多中心研究，对328名有机会参与I期试验的晚期癌症患者进行调查。作者询问患者对治疗益处和毒性的概率估计、他们的相对健康存量、风险偏好以及生活质量的重要性。
在控制与健康相关的生活质量后，相对健康存量增加10个百分点会使选择参与I期试验的几率降低16%（优势比=0.84，95%置信区间=0.72，0.97）。
相对健康存量会影响晚期癌症患者的治疗决策。
